BDSX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

BD

Mkt Cap

$249.5M

Volume

76.92K

Next Earnings

November 2nd

Loading chart

BD

BDSXBiodesix, Inc. Common Stock

BDSX

Pay with—

Available Balance0.00

BD

Mkt Cap

$249.6M

Volume

76.92K

Next Earnings

November 2nd

Chart Financials Earnings News About Insider Filings

Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026Biodesix announced multiple presentations at CHEST 2026 showcasing real-world evidence for integrating Nodify Lung blood-based testing into routine lung nodule management. The presentations include sponsored research comparing biomarkers with PET imaging, independent studies on patient follow-up adherence, and analyses from the CLARIFY study involving over 2,000 patients. The company is demonstrating how blood-based biomarkers can be incorporated into structured care pathways alongside imaging.GlobeNewswire Inc. · Oct 13, 2026

Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in FocusZacks Research showcased strong performance across its various investment portfolios and rating systems during the week ended October 2, 2026. Multiple stocks received upgrades and delivered significant gains, including CRCT and PGEN surging 32% and 30.8% respectively following recommendation upgrades. The Zacks Rank #1 portfolio outperformed the S&P 500 by 2.3 percentage points year-to-date, while the Focus List portfolio returned 19.86% versus 13.14% for the S&P 500 through August 31, 2026.Zacks Investment Research · Oct 5, 2026

Biodesix to Participate in Upcoming Investor ConferencesBiodesix, Inc. announced its participation in three upcoming investor conferences in September 2026. The company reported Q2 2026 revenue of $26.9 million, representing 34% growth, with an 82% gross margin. Biodesix maintained its FY 2026 revenue guidance of $108-114 million, reflecting 25% growth expectations.GlobeNewswire Inc. · Sep 3, 2026

Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026Biodesix, Inc. (Nasdaq: BDSX) announced it will release second quarter 2026 financial results on August 5, 2026 after market close, followed by a management conference call and webcast at 4:30 p.m. ET to discuss results and provide a business update.GlobeNewswire Inc. · Jul 22, 2026

Biodesix to Participate in Upcoming Investor ConferencesBiodesix, Inc. (Nasdaq: BDSX) announced that its leadership team will participate in three upcoming investor conferences in May and June 2026, including Craig-Hallum, William Blair Growth Stock Conference, and TD Cowen Annual Tools/Dx Revolution. The company will hold 1x1 meetings and present at select events, with presentations available for webcast replay.GlobeNewswire Inc. · May 21, 2026

Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026Biodesix, Inc. (Nasdaq: BDSX) announced it will release first quarter 2026 financial results on May 4, 2026, after market close, followed by a management conference call and webcast at 4:30 p.m. ET to discuss results and provide a business update.GlobeNewswire Inc. · Apr 20, 2026

Biodesix to Participate in Upcoming Investor ConferencesBiodesix, Inc. announced preliminary Q4 2025 revenue of $28.8 million (41% increase) and full-year 2025 revenue of $88.5 million (24% increase). The company affirmed guidance for Adjusted EBITDA positivity in Q4 2025. Management will participate in investor conferences in March 2026.GlobeNewswire Inc. · Feb 24, 2026

Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026Biodesix reported estimated Q4 2025 revenue of $28.8 million (41% increase) and full-year 2025 revenue of $88.5 million (24% increase). The company affirmed guidance for Adjusted EBITDA positivity in Q4 and plans to present clinical utility data for its Nodify Lung tests at upcoming scientific meetings.GlobeNewswire Inc. · Feb 12, 2026

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)Biodesix reported Q4 2025 revenue of $28.8 million (41% increase) and full-year revenue of $88.5 million (24% increase), exceeding guidance. Lung Diagnostics revenue grew 47% in Q4 driven by increased test volumes and reimbursement expansion. The company affirmed expectations for positive Adjusted EBITDA in Q4 2025.GlobeNewswire Inc. · Jan 12, 2026

Biodesix to Participate in Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) ConferenceBiodesix's CFO Robin Cowie will host investor meetings at the Lake Street Capital Markets' 9th Annual Best Ideas Growth Conference in New York on September 11, 2025.GlobeNewswire Inc. · Sep 5, 2025

to start trading

BD

BDSXBiodesix, Inc. Common Stock

BDSX

Pay with—

Available Balance0.00

Your PositionYou don't own any BDSX yet.

Related Tickers

Earnings